Guest Blog–National Cancer Institute’s CCDI Molecular Characterization Initiative Adds Rare Tumors
Children, adolescents, and young adults (AYAs) with newly diagnosed rare tumors are now eligible to enroll in the CCDI Molecular Characterization Initiative. Rare tumors are childhood cancers that have a low number of patients, which have been hard to study and understand. Potential participants must also be receiving care from a Children’s Oncology Group-affiliated hospital.
Enrollment is still also open to children and AYAs with central nervous system tumors and soft tissue sarcomas. The initiative will continue to expand to children and AYAs outside of Children’s Oncology Group–affiliated hospitals, those with other childhood cancers, and those whose cancer has returned.
Categories
- Blog Posts (65)
- Guest Blogs (18)
- Member Blogs (24)
- Survivorship Matters Blog (9)
- CAC2 News (22)
- Collaborative Achievements (13)
- Community News (170)
- News Digest (130)
- Research Explained (10)
- Webinars (62)
Tags
#CancelChildhoodCancer (1)
Advocacy (47)
Annual Summit (7)
Awareness (20)
AYA (2)
Best Practices (12)
Biorepositories (2)
CAC2 News (8)
CAC2 Project Incubator (1)
CAC2 Projects (11)
Call to Action (24)
Cancer Moonshot (1)
Clinical Trials (10)
COG (2)
Collaboration (11)
Comparative Oncology (1)
Data (15)
Delayed Diagnosis (2)
Digest (12)
Drug Development (12)
Drug Shortages (2)
Ethics (1)
Family Support (14)
FDA (1)
Funding Research (6)
Genomics (6)
Industry Perspective (5)
Member Access (12)
NCI (3)
Nutrition (1)
Patient-Reported Outcomes (1)
Prevention (5)
Psychosocial Support (4)
Rare and Ultra Rare Cancer (1)
Rare Cancers (1)
Regulations (3)
Research (38)
Research Advocacy (1)
Survivorship (26)
Venture Philanthropy (3)